No­var­tis and Sam­sung ink five-year, $309M ex­pan­sion to bi­o­log­ics man­u­fac­tur­ing part­ner­ship

Sam­sung Bi­o­log­ics dis­closed Mon­day that it’s sig­nif­i­cant­ly ex­pand­ing a 2022 pact with No­var­tis to help with the Swiss com­pa­ny’s bi­o­log­ics man­u­fac­tur­ing.

The orig­i­nal $81 mil­lion part­ner­ship from June 2022 will now be a five-year deal worth al­most $391 mil­lion — a $309 mil­lion ex­pan­sion.

A No­var­tis spokesper­son said via email that the com­pa­ny signed a let­ter of in­tent with Sam­sung Bi­o­log­ics “to re­serve the need­ed ca­pac­i­ty for the man­u­fac­tur­ing of bi­o­log­ics drug sub­stances. With the agree­ment in place, Sam­sung Bi­o­log­ics fa­cil­i­ty in Ko­rea would serve as an ad­di­tion­al sup­ply point for Eu­rope and oth­er mar­kets with grow­ing de­mand for No­var­tis bi­o­log­ics.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER